Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.65 EUR -2.99% Market Closed
Market Cap: 14.7m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

Celyad Oncology SA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celyad Oncology SA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Celyad Oncology SA
XBRU:CYAD
Cash from Financing Activities
€11.6m
CAGR 3-Years
3%
CAGR 5-Years
59%
CAGR 10-Years
N/A
M
MDxHealth SA
NASDAQ:MDXH
Cash from Financing Activities
$5.6m
CAGR 3-Years
-42%
CAGR 5-Years
N/A
CAGR 10-Years
17%
Galapagos NV
AEX:GLPG
Cash from Financing Activities
-€4.5m
CAGR 3-Years
-65%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxurion NV
XBRU:OXUR
Cash from Financing Activities
€7.8m
CAGR 3-Years
N/A
CAGR 5-Years
148%
CAGR 10-Years
N/A
No Stocks Found

Celyad Oncology SA
Glance View

Market Cap
14.7m EUR
Industry
Biotechnology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

CYAD Intrinsic Value
0.03 EUR
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Celyad Oncology SA's Cash from Financing Activities?
Cash from Financing Activities
11.6m EUR

Based on the financial report for Jun 30, 2024, Celyad Oncology SA's Cash from Financing Activities amounts to 11.6m EUR.

What is Celyad Oncology SA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
59%

Over the last year, the Cash from Financing Activities growth was 225%. The average annual Cash from Financing Activities growth rates for Celyad Oncology SA have been 3% over the past three years , 59% over the past five years .

Back to Top